{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:17:09Z","timestamp":1792286229486,"version":"4.4.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>Prophylactic anticoagulant therapy is recommended to reduce the risk of venous thromboembolism (VTE) after total hip or knee arthroplasty, and has become the standard of care. Rivaroxaban is a novel oral medication that directly inhibits factor Xa for the prevention and treatment of thromboembolic conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method:<\/jats:title><jats:p>A meta-analysis of randomized controlled trials (RCTs) was performed to determine the efficacy and safety of rivaroxaban after total hip arthroplasty (THA) and total knee arthroplasty (TKA) surgery. We reviewed several databases including PubMed, the Cochrane Library, Embase and the US trial registry to detect appropriate RCTs for our meta-analysis. The primary efficacy outcome of this meta-analysis was the combination of any deep-vein thrombosis (DVT), non-fatal pulmonary embolism (PE), and death from any cause. The main safety outcome was bleeding events which included significant bleeding events, clinically relevant insignificant bleeding events, or minor events. Other end points were the number of patients who received blood transfusion the volume of transfused whole blood or red blood cells, and the volume of postoperative drainage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result:<\/jats:title><jats:p>Thirteen RCTs were included in this meta-analysis. This meta-analysis showed that the overall rate of VTE events, DVT, PE, and death were 1%, 6%,\u200a&lt;\u200a1% and &lt;\u200a1%, respectively, for patients receiving treatment with rivaroxaban after THA and TKA surgery. The subgroup analysis demonstrated rivaroxaban had more superior effects in THA patients. The pooled analysis of bleeding events showed that the overall rate of major bleeding events, overt bleeding events associated with fall in Hb of &gt;\u200a2\u200ag\/DL, clinically overt bleeding events leading to transfusion of\u200a&gt;\u200a2 units of blood, clinically overt bleeding events leading to further surgeries, and non-major bleeding events were\u200a&lt;\u200a1%,\u200a&lt;\u200a1%,\u200a&lt;\u200a1%,\u200a&lt;\u200a1%, and 3%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>This is the first systematic review of the literature providing incidence of efficacy and safety outcomes for thromboprophylaxis in THA and TKA patients. Moreover, this meta-analysis showed that rivaroxaban had more superior effect in THA patients.<\/jats:p><\/jats:sec>","DOI":"10.1097\/md.0000000000014539","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T20:42:28Z","timestamp":1551386548000},"page":"e14539","source":"Crossref","is-referenced-by-count":22,"title":["Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement"],"prefix":"10.1097","volume":"98","author":[{"given":"Jichao","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Sanerlingyi Hospital, Hanzhong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Sanerlingyi Hospital, Hanzhong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yan","sequence":"additional","affiliation":[{"name":"Second Department of Orthopaedics, Shaanxi Traditional Chinese Medicine Hospital, Xian"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Osteoarthropathy, The WenDeng Osteopath Hospital, Weihai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jor.22139","article-title":"Epidemiology and risk factors for perioperative mortality after total hip and knee arthroplasty","volume":"30","author":"Memtsoudis","year":"2012","journal-title":"J Orthop Res"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00264-013-2134-8","article-title":"Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations","volume":"38","author":"Kinov","year":"2014","journal-title":"Int Orthop"},{"key":"R3-20230914","first-page":"799","article-title":"Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events","volume":"89","author":"Warwick","year":"2007","journal-title":"Bone Joint J"},{"issue":"(Suppl 1)","key":"R4-20230914","first-page":"I-4","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"White","year":"2003","journal-title":"Circulation"},{"issue":"(suppl 1)","key":"R5-20230914","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of venous thromboembolism","volume":"119","author":"Geerts","year":"2001","journal-title":"Chest J"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00264-011-1466-5","article-title":"Risk factors and distribution of symptomatic venous thromboembolism in total hip and knee replacements: prospective study","volume":"36","author":"Markovic-Denic","year":"2012","journal-title":"Int Orthop"},{"issue":"(suppl 2)","key":"R7-20230914","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest J"},{"issue":"(suppl 3)","key":"R8-20230914","doi-asserted-by":"crossref","first-page":"338S","DOI":"10.1378\/chest.126.3_suppl.338S","article-title":"Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"Geerts","year":"2004","journal-title":"Chest J"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.amjmed.2015.10.022","article-title":"Home treatment of deep venous thrombosis according to comorbid conditions","volume":"129","author":"Stein","year":"2016","journal-title":"Am J Med"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.thromres.2006.12.025","article-title":"Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"120","author":"Eriksson","year":"2007","journal-title":"Thromb Res"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement","volume":"4","author":"Eriksson","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","article-title":"A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement","volume":"114","author":"Eriksson","year":"2006","journal-title":"Circulation"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clin Pharmacokin"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-010-0889-z","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials","volume":"66","author":"Cao","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.thromres.2015.10.009","article-title":"Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis","volume":"136","author":"Feng","year":"2015","journal-title":"Thromb Res"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.avsg.2012.06.010","article-title":"Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin","volume":"27","author":"Yoshida Rde","year":"2013","journal-title":"Ann Vasc Surg"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"23726","DOI":"10.1038\/srep23726","article-title":"Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"6","author":"Ning","year":"2016","journal-title":"Sci Rep"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"R20-20230914","first-page":"6","article-title":"Oral rivaroxaban compared with subcutaneous enoxaparin for extended thrombopro-phylaxis after total hip arthroplasty: The RECORD1 Trial","author":"Eriksson","year":"2007","journal-title":"Am Soc Hematol"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(09)61553-1","article-title":"Rivaroxaban versus enoxaparin after total knee arthroplasty-Authors\u2019 reply","volume":"374","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/MBC.0000000000000121","article-title":"Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty","volume":"25","author":"Zou","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3760\/cma.j.issn.0366-6999.20132175","article-title":"Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial","volume":"127","author":"Jiang","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"R25-20230914","first-page":"255","article-title":"Comparison of switch-therapy modalities (enoxaparin to rivaroxaban\/dabigatran) and enoxaparin monotherapy after hip and knee replacement","volume":"49","author":"\u00d6zler","year":"2015","journal-title":"Acta Orthop Traumatol Turc"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"214","DOI":"10.11138\/jts\/2016.4.4.214","article-title":"Patient compliance with new oral anticoagulants after major orthopaedic surgery: rivaroxaban and dabigatran compared with subcutaneous injection of fondaparinux","volume":"4","author":"Di Benedetto","year":"2016","journal-title":"Joints"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/TCRM.S129077","article-title":"Intermittent pneumatic compression devices combined with anticoagulants for prevention of symptomatic deep vein thrombosis after total knee arthroplasty: a pilot study","volume":"13","author":"Liu","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ: Br Med J"},{"issue":"(Suppl 6)","key":"R30-20230914","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest J"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/bmj.39174.678032.AD","article-title":"Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance","volume":"334","author":"Hill","year":"2007","journal-title":"BMJ: Br Med J"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1677-54492011000200009","article-title":"New anticoagulants for the prophylaxis of venous thromboembolism","volume":"10","author":"Yoshida","year":"2011","journal-title":"J Vasc Brasileiro"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.thromres.2015.02.008","article-title":"Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials","volume":"135","author":"Ma","year":"2015","journal-title":"Thromb Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903010-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T07:50:53Z","timestamp":1721029853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903010-00010"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014539","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}